Aethlon Medical (OTCQB: AEMD) today disclosed data relating to the Companys Hemopurifier use in the successful treatment of patient with advanced Ebola infection. The data was presented by Dr. Helmut Geiger at the American Society of Nephrology (ASN) Annual Meeting, in which he reported that 242 million Ebola viruses were captured within the Hemopurifier during treatment of the patient; this number has been verified by a post-treatment elution protocol. The patient, a Ugandan physician infected in Sierra Leone, was not administered with Hemopurifier therapy until 12 days after being diagnosed. At the time of administration, he was unconscious and suffering from multiple organ failure, which required mechanical ventilation, continuous dialysis and the administration of vasopressor medications. Prior to administration of a single 6.5-hour Hemopurifier treatment the patients viral load was measured 400,000 virus copies per milliliter blood (copies/ml). Post treatment viral load was measured at 1,000 copies/ml and never rose again above that level. The treatment was well tolerated with no adverse events reported. Since administration of Hemopurifier therapy, hospital officials have reported that Ebola virus is no longer detectable in the patients blood and full recovery is expected.bit.ly/1xEDSw9
Posted on: Fri, 14 Nov 2014 17:58:04 +0000